Irvine CA USA February 14, 2008

Gencom announced today that the Company has extended the capabilities of its Genesys In-Silico Drug Discovery Optimization platform to include Genotoxic degradation modeling.

Genotoxicity testing is commonly carried out in preclinical trials in mice, but the new in-silico methodologies developed by Gencom will advance screening capabilities, speed and accuracy and reduce the number of animals that are exposed to experimental drugs.

The company already has in-silico micronucleus capabilities for genotoxicity testing and is in the final stages of validation for inclusion of the expanded modeling capabilities in the next release of Genesys.

The in-silico micronucleus assay is being increasingly used as the 'gold standard' for detecting a chemical's genotoxic potential as an alternative to the more costly and time-consuming chromosome aberration assay.

A micronucleus is small nucleus that forms during the process of cell division. Normally genetic material will be divided equally between the two daughter cells.

However if a chromosome has been damaged and broken - for example after exposure to a genotoxic compound - the genetic fragment may fail to be included in either of the nuclei and will be left behind to form a micronucleus.

According to Linc Travella, Chief Science Officer at Gencom, "these tests have traditionally been carried out by microscopic inspection. This is a very labor intensive way to determine the number of micronuclei in a sample, as a huge number of cells need to be counted."

He went on to say that "while a microscopist may be able to study 4,000 cells in an hour, Gencom's patented in-silico micronucleus modeling can count up to 2,000,000 cells or variants in less than a second."